Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An evaluation of artificial intelligence assisted prostate biopsy reporting in the Articulate Pro study.

NPJ digital medicine·2026
Same author

Use of UK national health databases for detecting intra-cranial aneurysm rupture in the Risk of Aneurysm Rupture (ROAR) study.

PLOS digital health·2026
Same author

Full BLOOD count TRends for colorectal cAnCer deteCtion (BLOODTRACC): external validation of dynamic clinical prediction models for early detection of colorectal cancer in primary care.

BMC cancer·2026
Same author

Estimating Rupture Risk of Intracranial Aneurysms: What We Know, What We Do Not Know, and What We Need.

Stroke·2026
Same author

A UK national prospective cohort study investigating current practices in single-event multilevel surgery for children with bilateral cerebral palsy and its impact on gait and function: the CPinBOSS study.

The bone & joint journal·2025
Same author

The one health threat of African horse sickness: Are Europe or the Middle East next?

Equine veterinary journal·2025

Related Experiment Video

Updated: May 9, 2026

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
05:12

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis

Published on: November 22, 2024

Galantamine for vascular cognitive impairment.

Jacqueline Birks1, David Craig

  • 1Centre for Statistics inMedicine, University of Oxford, Oxford, UK. jacqueline.birks@csm.ox.ac.uk.

The Cochrane Database of Systematic Reviews
|July 18, 2013
PubMed
Summary

Galantamine may offer benefits for cognition and daily living in vascular cognitive impairment, but it also increases adverse events and drop-out rates. More research is needed to confirm its efficacy and safety in treating vascular dementia.

Related Experiment Videos

Last Updated: May 9, 2026

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
05:12

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis

Published on: November 22, 2024

Area of Science:

  • Neurology
  • Pharmacology
  • Geriatrics

Background:

  • Vascular dementia is the second leading cause of dementia, often co-occurring with Alzheimer's disease as mixed dementia.
  • Current treatments for vascular cognitive impairment (VCI) are limited, despite its prevalence, particularly in older adults.
  • Galantamine, a cholinesterase inhibitor, is being investigated for VCI due to shared cholinergic deficits with Alzheimer's disease.

Purpose of the Study:

  • To evaluate the effectiveness of galantamine in treating individuals diagnosed with vascular cognitive impairment, vascular dementia, or mixed dementia.
  • To synthesize evidence from randomized controlled trials on galantamine's impact on cognitive function, daily activities, and behavior in VCI patients.

Main Methods:

  • A systematic review of unconfounded, randomized, double-blind, placebo-controlled trials was conducted.
  • Trials were identified through extensive database searches (MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS) and registries.
  • Data extraction and analysis were performed independently by two review authors.

Main Results:

  • Two trials involving 1378 participants showed statistically significant improvements favoring galantamine in cognition (ADAS-cog) and activities of daily living (DAD) in the overall population.
  • However, both trials reported significantly higher dropout rates and adverse events, particularly gastrointestinal side-effects, in the galantamine group compared to placebo.
  • One trial indicated a potential negative impact of galantamine on behavior (NPI), while the other showed a benefit.

Conclusions:

  • Available data suggest a potential benefit of galantamine for cognition and global clinical status in vascular dementia and VCI.
  • Galantamine use was associated with increased gastrointestinal side-effects and higher dropout rates in the included studies.
  • Further research is necessary to establish definitive conclusions regarding the efficacy and safety of galantamine for vascular cognitive impairment.